Therapeutic options in Alzheimer's disease (Q36511328)

14 August 2017

1 reference

title

Therapeutic options in Alzheimer's disease (English)

1 reference

14 August 2017

0 references

5

1 reference

14 August 2017

Paula I Moreira

1

0 references

Xiongwei Zhu

series ordinal

2

object named as

Xiongwei Zhu

1 reference

14 August 2017

4

Mark A Smith

1 reference

14 August 2017

Akihiko Nunomura

3

1 reference

14 August 2017

1 June 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

6

1 reference

14 August 2017

897-910

1 reference

Pathways towards and away from Alzheimer's disease

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Paired helical filaments from Alzheimer disease patients contain cytoskeletal components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Current pharmacotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Notch oncoproteins depend on gamma-secretase/presenilin activity for processing and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Presenilin 1 in migration and morphogenesis in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Skeletal and CNS defects in Presenilin-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Mice lacking both presenilin genes exhibit early embryonic patterning defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Abeta-generating enzymes: recent advances in beta- and gamma-secretase research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

New trends in the design of drugs against Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Vaccines for Alzheimer's disease: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Immunotherapeutic Approaches to Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

The alpha-ketoglutarate dehydrogenase complex in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Therapeutic potential of oxidant mechanisms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Predicting the failure of amyloid-beta vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Estrogen and Alzheimer's disease: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Estrogen levels do not correlate with improvement in cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Estrogen and cognition, with a focus on Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Oxidative damage in the olfactory system in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Idebenone treatment fails to slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

(R)-alpha-lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Dietary intake of antioxidants and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Antioxidant vitamin intake and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Evidence for the role of gonadotropin hormones in the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Oxidative stress signalling in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.6.897

21 January 2018

Identifiers

DOI

10.1586/14737175.6.6.897

1 reference

14 August 2017

1 reference

PubMed ID

16784412